Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Russia patents space station designed to generate artificial gravity - 2Which Exhibition hall Do You Suggest? Vote
- 3Vote in favor of your Number one natural product
- 47 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
- 5Reactions as Artemis II astronauts lift off on historic lunar mission
- How to watch 'A Charlie Brown Christmas' for free this weekend
- Top 20 Style Brands for Pioneers
- From Certificate to Dollars: College Majors with Extraordinary Monetary Prizes
- This Tiny Neon Frog Dwells in the Clouds
- Verdicts against social media companies carry consequences. But questions linger
- Consumer outlook on UK economy falls to two-year low
- Hezbollah uses ambulances, paramedic uniforms, as disguise for terrorist activity, IDF says
- Step by step instructions to Protect Your Senior Condo for Ideal Wellbeing and Solace
- Sustaining Public activity and Connections: Key Methodologies
